203
Views
26
CrossRef citations to date
0
Altmetric
Original Article

Monitoring C-reactive protein levels to predict favourable clinical outcomes from tocilizumab treatment in patients with rheumatoid arthritis

, , , , , , , , , , , , , , , , , , , & show all
Pages 977-985 | Received 03 Jul 2012, Accepted 04 Oct 2012, Published online: 02 Jan 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Moe Yamashita, Tetsuo Kobayashi, Satoshi Ito, Chihiro Kaneko, Akira Murasawa, Hajime Ishikawa & Koichi Tabeta. (2020) The periodontal inflamed surface area is associated with the clinical response to biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a retrospective study. Modern Rheumatology 30:6, pages 990-996.
Read now
Shuji Asai, Masatoshi Hayashi, Masahiro Hanabayashi, Yasuhide Kanayama, Toki Takemoto, Yuichiro Yabe, Tomone Shioura, Hisato Ishikawa, Yutaka Yoshioka, Takefumi Kato, Yuji Hirano, Takayoshi Fujibayashi, Yosuke Hattori, Tomonori Kobayakawa, Masahiko Ando, Yachiyo Kuwatsuka, Nobunori Takahashi, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Naoki Ishiguro & Toshihisa Kojima. (2020) Discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab: An interventional study. Modern Rheumatology 30:3, pages 434-441.
Read now
Hao Xue, Guang Yuan, Xing Guo, Qinglin Liu, Jinsen Zhang, Xiao Gao, Xiaofan Guo, Shugang Xu, Tong Li, Qianqian Shao, Shaofeng Yan & Gang Li. (2016) A novel tumor-promoting mechanism of IL6 and the therapeutic efficacy of tocilizumab: Hypoxia-induced IL6 is a potent autophagy initiator in glioblastoma via the p-STAT3-MIR155-3p-CREBRF pathway. Autophagy 12:7, pages 1129-1152.
Read now

Articles from other publishers (23)

Tetsuo Kobayashi, Satoshi Ito, Akira Murasawa, Hajime Ishikawa & Koichi Tabeta. (2023) Periodontitis severity affects the clinical response to biological disease-modifying antirheumatic drugs in rheumatoid arthritis: A 1-year follow-up study. Modern Rheumatology 33:1, pages 81-87.
Crossref
Tetsuo Kobayashi, Satoshi Ito, Akira Murasawa, Hajime Ishikawa & Koichi Tabeta. (2022) The serum immunoglobulin G titres against Porphyromonas gingivalis as a predictor of clinical response to 1-year treatment with biological disease-modifying antirheumatic drugs in rheumatoid arthritis patients: A retrospective cohort study . Modern Rheumatology.
Crossref
Mingyo Kim, Yong-ho Choe & Sang-il Lee. (2022) Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research. Immune Network 22:1.
Crossref
Patryk J. Drobinski, Anne C. Bay-Jensen, Morten A. Karsdal, Samra Sardar & Anne S. Siebuhr. (2021) Connective tissue remodelling is differently modulated by tocilizumab versus methotrexate monotherapy in patients with early rheumatoid arthritis: the AMBITION study. Arthritis Research & Therapy 23:1.
Crossref
Imke H. Bartelink, Pierre M. Bet, Nicolas Widmer, Monia Guidi, Erik Duijvelaar, Bram Grob, Richard Honeywell, Amanda Evelo, Ivo P. E. Tielbeek, Sue D. Snape, Henrike Hamer, Laurent A. Decosterd, Harm Jan Bogaard, Jurjan Aman & Eleonora L. Swart. (2021) Elevated acute phase proteins affect pharmacokinetics in COVID‐19 trials: Lessons from the CounterCOVID ‐ imatinib study. CPT: Pharmacometrics & Systems Pharmacology 10:12, pages 1497-1511.
Crossref
Shuji Asai, Nobunori Takahashi, Masatoshi Hayashi, Masahiro Hanabayashi, Yasuhide Kanayama, Toki Takemoto, Yuichiro Yabe, Tomone Shioura, Hisato Ishikawa, Yutaka Yoshioka, Takefumi Kato, Yuji Hirano, Takayoshi Fujibayashi, Yosuke Hattori, Tomonori Kobayakawa, Masahiko Ando, Yachiyo Kuwatsuka, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Naoki Ishiguro & Toshihisa Kojima. (2021) Facteurs prédictifs de poussée de polyarthrite rhumatoïde après arrêt du méthotrexate dans un traitement combiné avec du tocilizumab. Revue du Rhumatisme 88:5, pages 354-361.
Crossref
Shuji Asai, Nobunori Takahashi, Tomonori Kobayakawa, Atsushi Kaneko, Tatsuo Watanabe, Takefumi Kato, Tsuyoshi Nishiume, Hisato Ishikawa, Yutaka Yoshioka, Yasuhide Kanayama, Tsuyoshi Watanabe, Yuji Hirano, Masahiro Hanabayashi, Yuichiro Yabe, Yutaka Yokota, Mochihito Suzuki, Kenya Terabe, Naoki Ishiguro, Shiro Imagama & Toshihisa Kojima. (2021) Comparison of the effects of baricitinib and tocilizumab on disease activity in patients with rheumatoid arthritis: a propensity score matching analysis. Clinical Rheumatology 40:8, pages 3143-3151.
Crossref
Shuji Asai, Nobunori Takahashi, Masatoshi Hayashi, Masahiro Hanabayashi, Yasuhide Kanayama, Toki Takemoto, Yuichiro Yabe, Tomone Shioura, Hisato Ishikawa, Yutaka Yoshioka, Takefumi Kato, Yuji Hirano, Takayoshi Fujibayashi, Yosuke Hattori, Tomonori Kobayakawa, Masahiko Ando, Yachiyo Kuwatsuka, Takuya Matsumoto, Nobuyuki Asai, Yasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Naoki Ishiguro & Toshihisa Kojima. (2020) Predictors of disease flare after discontinuation of concomitant methotrexate in Japanese patients with rheumatoid arthritis treated with tocilizumab. Joint Bone Spine 87:6, pages 596-602.
Crossref
Hernando Trujillo, Fernando Caravaca‐Fontán, Ángel Sevillano, Eduardo Gutiérrez, Mario Fernández‐Ruiz, Francisco López‐Medrano, Ana Hernández, José María Aguado, Manuel Praga & Amado Andrés. (2020) Tocilizumab use in Kidney Transplant Patients with COVID‐19. Clinical Transplantation 34:11.
Crossref
Toshinori Hirai, Ayako Funaki, Kumi Murakami, Kazuhiko Hanada & Toshimasa Itoh. (2020) Effects of overweight and underweight on the treatment outcomes of rheumatoid arthritis patients treated with biological drugs: A retrospective observational descriptive study. Journal of Clinical Pharmacy and Therapeutics 45:4, pages 666-673.
Crossref
Daniel Aletaha. (2020) Precision medicine and management of rheumatoid arthritis. Journal of Autoimmunity 110, pages 102405.
Crossref
Yoshiya Tanaka, Kazuteru Wada, Yoshinori Takahashi, Owen Hagino, Hubert van Hoogstraten, Neil M. H. Graham & Hideto Kameda. (2019) Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. Arthritis Research & Therapy 21:1.
Crossref
Marketa Bloomfield, Zuzana Parackova, Tamara Cabelova, Iva Pospisilova, Pavel Kabicek, Hana Houstkova & Anna Sediva. (2019) Anti-IL6 Autoantibodies in an Infant With CRP-Less Septic Shock. Frontiers in Immunology 10.
Crossref
Jian Chen, Meng-shi Tang, Li-chang Xu, Shu Li, Yan Ge, Jin-feng Du, Xi Xie, Jing Tian, Jin-wei Chen & Fen Li. (2019) Proteomic analysis of biomarkers predicting the response to triple therapy in patients with rheumatoid arthritis. Biomedicine & Pharmacotherapy 116, pages 109026.
Crossref
Makoto Takada, Yoshihito Ohba, Seitaro Kamiya, Tsutomu Kabashima & Kenichiro Nakashima. (2019) Simple and rapid analysis of tocilizumab using HPLC‐fluorescence detection method. Luminescence 34:3, pages 347-352.
Crossref
Nagaraja Haleagrahara, Kelly Hodgson, Socorro Miranda-Hernandez, Samuel Hughes, Anupama Bangra Kulur & Natkunam Ketheesan. (2018) Flavonoid quercetin–methotrexate combination inhibits inflammatory mediators and matrix metalloproteinase expression, providing protection to joints in collagen-induced arthritis. Inflammopharmacology 26:5, pages 1219-1232.
Crossref
Cesar Diaz-Torne, Maria dels Angels Ortiz, Patricia Moya, Maria Victoria Hernandez, Delia Reina, Ivan Castellvi, Juan Jose De Agustin, Diana de la Fuente, Hector Corominas, Raimon Sanmarti, Carlos Zamora, Elisabet Cantó & Silvia Vidal. (2018) The combination of IL-6 and its soluble receptor is associated with the response of rheumatoid arthritis patients to tocilizumab. Seminars in Arthritis and Rheumatism 47:6, pages 757-764.
Crossref
Dagur Ingi Jonsson, Ritva Pirskanen & Fredrik Piehl. (2017) Beneficial effect of tocilizumab in myasthenia gravis refractory to rituximab. Neuromuscular Disorders 27:6, pages 565-568.
Crossref
Sanjay Singh. 2017. Oxidative Stress: Diagnostic Methods and Applications in Medical Science. Oxidative Stress: Diagnostic Methods and Applications in Medical Science 65 95 .
Javier Narváez, Berta Magallares, César Díaz Torné, Maria Victoria Hernández, Delia Reina, Héctor Corominas, Raimon Sanmartí, Josep Maria LLobet, Arturo Rodriguez de la Serna & Joan Miquel Nolla. (2016) Predictive factors for induction of remission in patients with active rheumatoid arthritis treated with tocilizumab in clinical practice. Seminars in Arthritis and Rheumatism 45:4, pages 386-390.
Crossref
Keisuke Izumi, Yuko Kaneko, Misato Hashizume, Keiko Yoshimoto & Tsutomu Takeuchi. (2015) Baseline Serum Osteopontin Levels Predict the Clinical Effectiveness of Tocilizumab but Not Infliximab in Biologic-Naïve Patients with Rheumatoid Arthritis: A Single-Center Prospective Study at 1 Year (the Keio First-Bio Cohort Study). PLOS ONE 10:12, pages e0145468.
Crossref
Helena Forsblad-d’Elia, Karin Bengtsson, Lars Erik Kristensen & Lennart T. H. Jacobsson. (2015) Drug adherence, response and predictors thereof for tocilizumab in patients with rheumatoid arthritis: results from the Swedish biologics register. Rheumatology 54:7, pages 1186-1193.
Crossref
Qing Chang, Laura Daly & Jacqueline Bromberg. (2014) The IL-6 feed-forward loop: A driver of tumorigenesis. Seminars in Immunology 26:1, pages 48-53.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.